Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • AZD8055: Technical Protocols for mTOR Pathway Inhibition

    2026-08-03

    AZD8055: Technical Protocols for mTOR Pathway Inhibition

    What This Product Solves

    AZD8055 (SKU A8214, APExBIO) is an ATP-competitive, dual mTORC1/mTORC2 inhibitor, precisely targeting the mTOR kinase with high selectivity. It is designed for preclinical research requiring robust inhibition of both mTOR complexes, which regulate cell growth, proliferation, and survival. AZD8055 is especially valuable for dissecting PI3K/Akt/mTOR signaling pathways in cancer and metabolic models, enabling researchers to validate mechanistic hypotheses regarding mTOR regulation. Its nanomolar potency and kinase selectivity profile make it suitable for experiments where off-target effects must be minimized. AZD8055 is not appropriate for protocols focused on clinical efficacy or where water solubility is essential.

    Protocol Parameters

    • Assay: Cell proliferation inhibition
      Value: Effective at nanomolar concentrations (e.g., IC50 = 0.8 nM)
      Applicability: Use in in vitro cancer cell line models to assess mTOR pathway contribution to proliferation.
      Rationale: Direct from product data; enables precise titration and rapid response readouts.
      Source type: product information
    • Assay: Compound solubilization
      Value: Soluble at ≥23.3 mg/mL in DMSO; insoluble in water/ethanol
      Applicability: Prepare concentrated stock solutions in anhydrous DMSO; avoid aqueous or ethanol-based vehicles.
      Rationale: Ensures consistent delivery and avoids precipitation or loss of potency.
      Source type: product information
    • Assay: Storage conditions
      Value: Store solid at -20°C; use solutions promptly, avoid long-term storage
      Applicability: Maintain compound integrity and activity, especially for repeated freeze-thaw cycles.
      Rationale: Reduces risk of degradation and ensures reproducibility.
      Source type: product information
    • Assay: Animal dosing (intraperitoneal injection)
      Value: Not specified; refer to published preclinical models for guidance
      Applicability: Use in xenograft or metabolic studies where systemic mTOR inhibition is required.
      Rationale: Product dossier confirms in vivo modulation of glucose and insulin; dose requires optimization.
      Source type: Workflow recommendation

    Workflow Setup and QC Checklist

    • Compound Handling: Weigh AZD8055 powder quickly at room temperature; immediately return to -20°C storage. Avoid moisture exposure.
    • Stock Preparation: Prepare concentrated stocks in 100% DMSO. Vortex thoroughly until fully dissolved. Filter sterilize if needed, but minimize freeze-thaw cycles.
    • Aliquoting: Divide stock solutions into single-use aliquots to prevent repeated freeze-thaw degradation.
    • Vehicle Control: Always include DMSO-only controls at equivalent final concentrations to account for vehicle effects on cells or animals.
    • Cell-Based Assays: Optimize seeding density and compound exposure time. For proliferation studies, measure markers like Ki67 post-treatment at nanomolar ranges.
    • In Vivo Studies: Solubilize in DMSO, then dilute with compatible non-aqueous vehicles for injection; avoid water and ethanol. Confirm solubility visually before dosing.
    • QC Checkpoints: Document batch number, preparation date, and storage history for each experiment. Validate activity with a known responsive cell line prior to novel applications.

    Common Failure Modes and Fixes

    • Precipitation in Aqueous Media: AZD8055 is insoluble in water and ethanol. If precipitation occurs, reformulate stocks in DMSO and ensure dilution into media does not exceed DMSO tolerability for the assay.
    • Loss of Potency: Degradation may occur with repeated freeze-thaw cycles or prolonged solution storage. Use freshly prepared aliquots and minimize handling time at room temperature.
    • Vehicle Toxicity: High DMSO concentrations can affect cell viability independent of AZD8055. Always match vehicle concentration in control wells or animals and keep final DMSO below standard cell culture tolerances (typically ≤0.1–0.5%).
    • Variability in Response: If expected pathway inhibition or phenotype is not observed, verify cell line authentication, confirm batch activity, and check for mycoplasma contamination.
    • Inconsistent In Vivo Results: If glucose or insulin modulation is not observed, confirm proper formulation, dosing schedule, and injection technique. Adjust vehicle or delivery method as needed.

    Scope and Limitations

    AZD8055 is a research-use-only reagent for mechanistic studies of mTOR signaling. It is not recommended for protocols requiring water-soluble compounds or for studies aiming to claim clinical efficacy, as late-stage trials have shown minimal benefit. For translational applications, alternative compounds or additional validation is necessary. In addition, as with all kinase inhibitors, off-target liabilities should be assessed in the context of each experimental system, despite the compound’s high selectivity profile. AZD8055 is best deployed in models where dual mTORC1/mTORC2 inhibition is critical for dissecting PI3K/Akt/mTOR pathway dynamics. For further detailed protocol advice, see Practical Guidance for mTOR Pathway Inhibition (setup and troubleshooting) and Technical Guidance for mTOR Inhibitor Use (mechanistic study recommendations).

    Conclusion

    AZD8055 is a highly selective mTOR kinase inhibitor optimized for preclinical mechanistic studies of the mTOR signaling pathway. Its dual inhibition of mTORC1 and mTORC2, combined with nanomolar potency and limited off-target activity, make it a robust choice for cancer and metabolic research workflows where precise pathway perturbation is required. Researchers should implement careful compound handling, validated solubilization, and strict vehicle controls to ensure reproducible results. For further technical details and recommended best practices, consult the APExBIO product page.